Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Basem M Mishriky"'
Publikováno v:
Primary Care Diabetes. 16:471-473
Given the CV benefit noted in the CVOTs, GLP-1RAs and SGLT-2is are given preference in T2DM guidelines. While guidelines do not report potential gender difference, those differences exist. On restricting the CVOTs results to women with increased CV r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36310f0cae2fd052454f69e419093195
https://doi.org/10.1016/j.pcd.2022.03.012
https://doi.org/10.1016/j.pcd.2022.03.012
Autor:
BASEM M. MISHRIKY, DOYLE M. CUMMINGS, YUANYUAN FU, JACQUIE HALLADAY, WILLIAM S. JONES, ANDREA BOAN, SARA JONES BERKELEY, SHIVAJIRAO P. PATIL, JAMES R. POWELL, ALYSSA ADAMS, WILLIAM IRISH
Publikováno v:
Diabetes. 71
While African Americans (AA) were underrepresented in the SGLT2i CVOT, the results from those trials were generalized to all, regardless of race. Our goal was to evaluate the risk of heart failure hospitalization (hHF) among AA vs. White (Wh) vs. His
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15460b1e82c0ca0b6e7a7bc83c68895c
https://doi.org/10.2337/db22-20-lb
https://doi.org/10.2337/db22-20-lb
Publikováno v:
Primary care. 49(2)
Diabetes-related microvascular complications include diabetic neuropathy (eg, diabetic symmetric polyneuropathy (DSPN), cardiac autonomic neuropathy, gastroparesis, enteropathy, erectile dysfunction, female sexual dysfunction, and hypoglycemia unawar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::626d12f14d3df7c553cd82597e3546d0
https://pubmed.ncbi.nlm.nih.gov/35595480
https://pubmed.ncbi.nlm.nih.gov/35595480
Publikováno v:
Diabetes, Obesity and Metabolism. 23:276-280
Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor that has recently been shown to reduce the incidence of reported episodes of atrial fibrillation (AF)/atrial flutter in the DECLARE-TIMI 58 trial. This raises the question regarding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc47da804cd5da41a5116dbccc260e86
https://doi.org/10.1111/dom.14211
https://doi.org/10.1111/dom.14211
Autor:
Muna R. Mian, Stephanie O. Page, Doyle M. Cummings, Shivajirao P. Patil, Jarrod Uhrig, James R. Powell, Kerry Sewell, Basem M. Mishriky
Publikováno v:
The Journal of Clinical Pharmacology. 60:980-991
Our aim was to explore whether the baseline hemoglobin A1c or the dose of sodium glucose cotransporter-2 inhibitor (SGLT-2i) chosen better predicted the efficacy of SGLT-2i versus dipeptidyl peptidase-4 inhibitor (DPP-4i) in type 2 diabetes. We searc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f6b81df4d49dbd58de292dffc4e5534
https://doi.org/10.1002/jcph.1599
https://doi.org/10.1002/jcph.1599
Autor:
Basem M Mishriky, Doyle M Cummings, Yuanyuan Fu, Jacquie Halladay, Schuyler Jones, Andrea Boan, Sara Jones, Shivajirao Patil, James Powell, Alyssa Adams, William Irish
Publikováno v:
Journal of the Endocrine Society. 6:A282-A282
The results from the SGLT-2 inhibitors cardiovascular outcome trials were generalized to all, despite that non-Hispanic Black (hereafter, "Black") participants were underrepresented. Our goal was to evaluate, among patients with type 2 diabetes, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::812cbc0e6f5982b96682363ef6c00aeb
https://doi.org/10.1210/jendso/bvac150.582
https://doi.org/10.1210/jendso/bvac150.582
Publikováno v:
Postgraduate Medicine. 131:376-382
Objective: To investigate the relationship between insulin use and clinical outcomes in patients with type 2 diabetes stratified by level of insulin resistance (IR).Methods: Cross sectional...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d909c9e77b05a2662181072e5ae0d3da
https://doi.org/10.1080/00325481.2019.1643635
https://doi.org/10.1080/00325481.2019.1643635
Autor:
Jennifer A. Wittwer, Qiang Wu, Basem M. Mishriky, Doyle M. Cummings, Jennifer X. Chu, James R. Powell, Kerry Sewell
Publikováno v:
Diabetes, Obesity and Metabolism. 21:2274-2283
Aims While recent cardiovascular safety trials (CVST) concerning newer diabetes medications included mostly white participants, results are being generalized to all races in recent guidelines. This raises a controversial question regarding the approp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6da6808bd4bde76bd28247783a2e5ddc
https://doi.org/10.1111/dom.13805
https://doi.org/10.1111/dom.13805
Publikováno v:
Diabetes & Metabolism. 45:102-109
Aims Our aim was to compare once-weekly semaglutide to incretin-based therapies – defined as either dipeptidyl peptidase-4 inhibitors (DPP-4i) or other glucagon-like peptide-1 receptor agonist (GLP-1RA) – in patients with type 2 diabetes. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65c378daaecf3eebd16f67402b41558a
https://doi.org/10.1016/j.diabet.2018.09.002
https://doi.org/10.1016/j.diabet.2018.09.002
Autor:
James R. Powell, Doyle M. Cummings, Zahra Sadat Hamedi, Basem M. Mishriky, Victor Okunrintemi
Publikováno v:
Diabetes/Metabolism Research and Reviews. 37
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73c209589eea6625d12c43a772f2a74b
https://doi.org/10.1002/dmrr.3436
https://doi.org/10.1002/dmrr.3436